{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T11:10:11Z","timestamp":1789211411198,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.jaip.2017.08.004","type":"journal-article","created":{"date-parts":[[2017,11,6]],"date-time":"2017-11-06T02:46:14Z","timestamp":1509936374000},"page":"1564-1571","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Rituximab Hypersensitivity: Evaluation, Desensitization, and Potential Mechanisms"],"prefix":"10.1016","volume":"5","author":[{"given":"Johnson T.","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidan","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2017.08.004_bib1","first-page":"66","article-title":"Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma","volume":"26","author":"Grillo-L\u00f3pez","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jaip.2017.08.004_bib2","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaip.2017.08.004_bib3","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/art.25034","article-title":"Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial","volume":"62","author":"Bingham","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaip.2017.08.004_bib4","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1186\/ar3337","article-title":"Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)","volume":"13","author":"Tony","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaip.2017.08.004_bib5","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1634\/theoncologist.2014-0113","article-title":"Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results\u2014Medicare analysis","volume":"19","author":"Hamlin","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.jaip.2017.08.004_bib6","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2165\/00003495-200363080-00005","article-title":"Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia","volume":"63","author":"Plosker","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.jaip.2017.08.004_bib7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2165\/11585960-000000000-00000","article-title":"Incidence of infusion-associated reactions with rituximab for treating multiple sclerosis: a retrospective analysis of patients treated at a US centre","volume":"34","author":"Brown","year":"2011","journal-title":"Drug Saf"},{"key":"10.1016\/j.jaip.2017.08.004_bib8","doi-asserted-by":"crossref","first-page":"S283","DOI":"10.1016\/S0190-9622(03)00744-8","article-title":"Hypocomplementemic urticarial vasculitis with angioedema, a rare presentation of systemic lupus erythematosus: rapid response to rituximab","volume":"49","author":"Saigal","year":"2003","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2017.08.004_bib9","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s00277-010-0997-y","article-title":"Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia","volume":"89","author":"Pe\u00f1alver","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jaip.2017.08.004_bib10","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.autrev.2014.11.014","article-title":"Efficacy and safety of rituximab in auto-immune hemolytic anemia: a meta-analysis of 21 studies","volume":"14","author":"Reynaud","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaip.2017.08.004_bib11","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s11926-010-0090-5","article-title":"The long-term impact of rituximab for childhood immune thrombocytopenia","volume":"12","author":"Cooper","year":"2010","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jaip.2017.08.004_bib12","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2017.08.004_bib13","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1007\/s10067-010-1412-8","article-title":"Essential mixed cryoglobulinemia type III with leukocytoclastic vasculitis: remission by rituximab","volume":"32","author":"Baerlecken","year":"2013","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jaip.2017.08.004_bib14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00296-009-1146-6","article-title":"Churg-Strauss syndrome successfully treated with rituximab","volume":"31","author":"D\u00f8nvik","year":"2011","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jaip.2017.08.004_bib15","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1200\/JCO.1999.17.3.791","article-title":"Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance","volume":"17","author":"Byrd","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaip.2017.08.004_bib16","first-page":"53","article-title":"Optimizing the use of rituximab for treatment of B-cell non-Hodgkin's lymphoma: a benefit-risk update","volume":"27","author":"Kunkel","year":"2000","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jaip.2017.08.004_bib17","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1080\/10428190127502","article-title":"Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosis","volume":"42","author":"Kanelli","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jaip.2017.08.004_bib18","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","article-title":"Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment","volume":"18","author":"Davis","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaip.2017.08.004_bib19","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2017.08.004_bib20","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaip.2017.08.004_bib21","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaip.2017.08.004_bib22","doi-asserted-by":"crossref","first-page":"125","DOI":"10.47102\/annals-acadmedsg.V41N3p125","article-title":"Incidence of infusion-related reaction to monoclonal antibody rituximab: a national kidney and transplant institute experience","volume":"41","author":"Montoya","year":"2012","journal-title":"Ann Acad Med Singapore"},{"key":"10.1016\/j.jaip.2017.08.004_bib23","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1111\/j.1756-185X.2011.01645.x","article-title":"Serum sickness and severe angioedema following rituximab therapy in RA","volume":"15","author":"Kumar","year":"2012","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.jaip.2017.08.004_bib24","first-page":"430","article-title":"Serum sickness following treatment with rituximab","volume":"34","author":"Todd","year":"2007","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.jaip.2017.08.004_bib25","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/annonc\/mdf350","article-title":"Stevens-Johnson syndrome after treatment with rituximab","volume":"13","author":"Lowndes","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaip.2017.08.004_bib26","first-page":"377","article-title":"Toxic epidermal necrolysis in two rhesus macaques (Macaca mulatta) after administration of rituximab","volume":"55","author":"Allen","year":"2005","journal-title":"Comp Med"},{"key":"10.1016\/j.jaip.2017.08.004_bib27","doi-asserted-by":"crossref","first-page":"680431","DOI":"10.1155\/2012\/680431","article-title":"Rituximab-induced bronchiolitis obliterans organizing pneumonia","volume":"2012","author":"Ergin","year":"2012","journal-title":"Case Rep Med"},{"key":"10.1016\/j.jaip.2017.08.004_bib28","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/ajh.21372","article-title":"Rituximab-associated acute thrombocytopenia: an under-diagnosed phenomenon","volume":"84","author":"Ram","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaip.2017.08.004_bib29","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1346-8138.2009.00639.x","article-title":"Rituximab-induced vasculitis: a case report and review of the medical published work","volume":"36","author":"Kim","year":"2009","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jaip.2017.08.004_bib30","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000051713","article-title":"Rituximab-induced vasculitis","volume":"203","author":"Dereure","year":"2001","journal-title":"Dermatol Basel Switz"},{"key":"10.1016\/j.jaip.2017.08.004_bib31","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.jaci.2009.02.042","article-title":"Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management","volume":"123","author":"Hesterberg","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.08.004_bib32","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaip.2013.08.011","article-title":"Oxaliplatin hypersensitivity: evaluation, implications of skin testing, and desensitization","volume":"2","author":"Wong","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2017.08.004_bib33","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1053\/ai.1994.v94.a55251","article-title":"Vancomycin hypersensitivity: synergism with narcotics and \u201cdesensitization\u201d by a rapid continuous intravenous protocol","volume":"94","author":"Wong","year":"1994","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2017.08.004_bib34","doi-asserted-by":"crossref","first-page":"304","DOI":"10.4168\/aair.2014.6.4.304","article-title":"The utility of serum tryptase in the diagnosis of food-induced anaphylaxis","volume":"6","author":"Wongkaewpothong","year":"2014","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.jaip.2017.08.004_bib35","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/j.1365-2222.1995.tb00007.x","article-title":"Tryptase and histamine release due to a sting challenge in bee venom allergic patients treated successfully or unsuccessfully with hyposensitization","volume":"25","author":"Eberlein-K\u00f6nig","year":"1995","journal-title":"Clin Exp Allergy"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219817306141?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219817306141?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:12:50Z","timestamp":1761973970000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219817306141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S2213219817306141"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2017.08.004","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab Hypersensitivity: Evaluation, Desensitization, and Potential Mechanisms","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2017.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}